DURECT Co. (NASDAQ:DRRX) Director Jon S. Saxe acquired 25,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was purchased at an average price of $0.55 per share, for a total transaction of $13,750.00. Following the transaction, the director now directly owns 27,810 shares of the company’s stock, valued at approximately $15,295.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of DRRX traded down $0.02 during trading hours on Wednesday, reaching $0.50. 8,225 shares of the company traded hands, compared to its average volume of 479,607. The firm has a market capitalization of $82.82 million, a price-to-earnings ratio of -3.13 and a beta of 1.88. The company has a current ratio of 3.74, a quick ratio of 3.39 and a debt-to-equity ratio of 1.82. DURECT Co. has a 12 month low of $0.46 and a 12 month high of $2.24.
DURECT (NASDAQ:DRRX) last announced its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $4.13 million for the quarter, compared to analyst estimates of $3.50 million. DURECT had a negative net margin of 125.76% and a negative return on equity of 108.92%. On average, research analysts forecast that DURECT Co. will post -0.19 EPS for the current fiscal year.
Separately, HC Wainwright restated a “buy” rating on shares of DURECT in a research report on Thursday, April 18th.
ILLEGAL ACTIVITY WARNING: “DURECT Co. (NASDAQ:DRRX) Director Buys $13,750.00 in Stock” was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/06/12/durect-co-nasdaqdrrx-director-buys-13750-00-in-stock.html.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.
See Also: Bull Market
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.